search: results update below


browse funds: selections are stored



recently rated:

Rated by 17
1.9
 

top rated funds:

Rated by 12
4.1

Rated by 12
4.0
 

Rated by 11
4.0
 

Rated by 15
4.0

Rated by 21
4.0

Rated by 41
3.9

Rated by 11
3.8

Rated by 44
3.8

Rated by 106
3.8

Rated by 32
3.8

Rated by 32
3.8

Rated by 64
3.7

Rated by 23
3.7

Rated by 27
3.7

Rated by 11
3.6

Rated by 18
3.6

Rated by 10
3.6
 

Rated by 62
3.6

Rated by 21
3.5

Rated by 12
3.5
 

Rated by 30
3.5

Rated by 28
3.4

Rated by 19
3.4

Rated by 14
3.4
 

Rated by 49
3.4
 

Rated by 16
3.4
 

Rated by 10
3.4

Rated by 13
3.4

Rated by 16
3.4

Rated by 60
3.4

Please take a moment and make a financial contribution to TheFunded. If we have helped you, help us with resources to further grow the both the site and our entrepreneur training program, The Founder Institute.

Member Post

TheFunded.com is an online community of over 20,000 CEOs, Founders and entrepreneurs to discuss fundraising, rate and review angel investors and venture capitalists, and discuss strategies to grow a startup business. Enjoy the site, and be sure to join us at our Founder Showcase events to meet the community.

Sign-up for Membership

0
Agree
1
Disagree

Early Stage Biopharma

TheFunded.com Discussion

Posted by Anonymous on 2008-02-23

Tags: Funding Sources

PUBLIC:

How are early stage biopharma companies getting funded these days" We have good pre-clinical data and are working to raise funds for a Phase I clinical trial. We've talked to several of the larger coastal funds who (for the most part) have been polite but consistently call us too early, which is consistent with their investment history in the sector. We need to raise between $5-7 million and are not on one of the coasts. This seems like an awkward space. I've had the opportunity to present to several of the top-tier VCs. Most of whom have been interested, engaged and polite BUT the truth is that their track record indicates they are not doing these deals. Their biopharma deals tend to be later stage and greater than $15 million. I understand deal flow but it seems like a waste of everyones time and gets back to the question "who funds early stage biopharma" Advise is greatly appreciated.